Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: Does hepatitis B immunoglobulin provide a survival advantage?

Transplant International

Volumn 24, Issue 6, 2011, Pages 570-581

  Brock, Guy N ^a   Mostajabi, Farida ^a   Ferguson, Nicole ^a   Carrubba, Christopher J ^b   Eng, Mary ^b   Buell, Joseph F ^b   Marvin, Michael R ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

hepatitis B core positive donors; hepatitis B immunoglobulin; lamivudine; liver transplantation; multiple imputation; survival analysis; United Network for Organ Sharing data

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; LAMIVUDINE;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DATA BASE; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION;

ADULT; ANTIVIRAL AGENTS; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; TISSUE DONORS;

EID: 79955558934     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01236.x     Document Type: Article

References (38)

1. Prokaso E, Strasser SI, Koorey DJ, Verran D, McCaughan GW,. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver trasnplant recipients from hepatitis B core-postitive donors. Clin Transplant 2006; 20: 369.
2. Douglas D, Rakela J, Wright T, Krom R, Wiesner R,. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transplant Surg 1997; 3: 105.
3. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ,. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 1058.
4. Dodson SF, Issa S, Araya V, et al. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 1582.
5. Prieto M, Gomez MD, Berenguer M, et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transplant 2001; 7: 51.
6. Manzarbeitia C, Reich D, Ortiz J, Rothstein K, Araya V, Munoz S,. Safe use of liver donors with positive hepatitis B core antibody. Liver Transplant 2002; 8: 556.
7. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997; 113: 1168.
8. Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59: 230.
9. Munoz SJ,. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transplant 2002; 8S1: S82.
10. Uemoto S, Sugiyama K, Marusawa H, et al. Transmission of hepatitis B virus from hepatitis B core antibody positive donors in living related liver transplants. Transplantation 1998; 65: 494.
11. Loss GE, Mason AL, Blazek J, et al. Transplantation of livers from HBcAb positive donors into HBcAb negative recipients: a strategy and preliminary results. Clin Transplant 2001; 15 (Suppl. 6): 55.
12. Holt D, Thomas R, Van Thiel D, Brems J,. Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation. Arch Surg 2002; 137: 572.
13. Yu AS, Vierling JM, Colquhoun SD, et al. Transmission of hepatitis B infection from hepatitis core antibody-positive liver allografts is prevented by lamivudine therapy. Liver Transplant 2001; 7: 513.
14. De Vera ME, Eghtesad D, Tom K, Liver transplantations of HBcAb+ and HCV+ allografts. Abstract, 1138. ATC 2005: 6th Annual Joint Meeting of the American Society of Transplant Surgeons and the American Society of Transplantation, May 2005.
15. Roque-Alfonso AM, Feray C, Samuel D, et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors. Gut 2002; 50: 95.
16. Dodson SF,. Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors. Clin Transplant 2000; 14S2: 20.
17. Vizzini G, Gruttadauria S, Volpes R, et al. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Clin Transplant 2011; 25: E77.
18. Avelino-Silva VI, D'Albuquerque LA, Bonazzi PR, et al. Liver transplant from anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Clin Transplant 2010; 24: 735.
19. Lok AS,. Prevention of recurrent hepatitis B post-liver transplantation. Liver Transpl 2002; 8: S67.
20. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 2006; 6: 783.
21. Wiesner RH, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91.
22. Cox DR, Regression models and life tables (with discussion). J Roy Stat Soc 1972; 34: 187.
23. Contal C, O'Quigley J,. An application of change point methods in studying the effect of age on survival in breast cancer. Computational Statistics Data Analysis 1999; 30: 253.
24. Klein JP, Moeschberger ML,. Survival Analysis, Techniques for Censored and Truncated Data, 2nd edn. New York: Springer-Verlag, Inc, 2003: pp 92-99.
25. Bursac Z, Gauss CH, Williams DK, Hosmer DW,. Purposeful selection of variables in logistic regression. Source Code for Biology and Medicine 2008; 3: 17.
26. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2007.
27. Clark TG, Altman DG,. Developing a prognostic model in the presence of missing data: an ovarian cancer case study. J Clin Epidemiol 2003; 56: 28.
28. Van Buuren S, Boshuizen HC, Knook DL,. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681.
29. Harrell FE,. Regression Modeling Strategies. New York: Springer-Verlag, 2001: pp 41-51.
30. Rosenbaum PR, Rubin DB,. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41.
31. Agresti A,. Categorical Data Analysis, 2nd edn. New Jersey: John Wiley & Sons, Hoboken, 2002: pp 267-274.
32. Chen YS, Wang CC, de Villa V, et al. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16: 405.
33. De Villa AH, Chen YS, Chen CL,. Hepatitis B core antibody-positive grafts: recipient's risk. Transplantation 2003; 75: S49.
34. Saab S, Chang AJ, Comulada S, et al. Outcomes of hepatitis C- and hepatitis B core anitbody-positive grafts in orthotopic liver transplantation. Liver Transplant 2003; 9: 1053.
35. Kwekkeboom J, Tha-In T, Tra WM, et al. Hepatitis B immunoglobulins inhibit dendritic cells and T cells and protect against acute rejection after liver transplantation. Am J Transplant 2005; 5: 2393.
36. Tha-In T, Metselaar HJ, Titanus HW, et al. Superior immunomodulatory effects of intravenous immunoglobulins on human T-cells and dendritic cells: comparison to calcineurin inhibitors. Transplantation 2006; 81: 1725.
37. Farges O, Saliba F, Farhamant H, et al. Incidence of rejection and infection after liver transplantation as a function of the primary disease: possible influence of alcohol and polyclonal immunoglobulins. Hepatology 1996; 23: 240.
38. Bucuvalas JC, Anand R,. Treatment with immunoglobulin improves outcome for pediatric liver transplant recipients. Liver Transpl 2009; 15: 1564.